Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A de Graeff

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|June 1, 1985
[The dangers of the sudden discontinuation of drugs]P A de Graeff
Agents and Actions. Supplements|January 1, 1992
The effect of bradykinin on coronary flow and its potentiation by SH-containing ACE-inhibitorsP A de Graeff, W H van Gilst
Agents and Actions. Supplements|January 1, 1992
Early ACE-inhibition in myocardial infarction. Possible role of bradykininW H van Gilst, P A de Graeff
Pharmacy World & Science : PWS|May 10, 2001
Comparative trials in registration files of cardiovascular drugs: comparator drugs and dosing schemesN F Wieringa, R Vos, P A de Graeff
Nederlands Tijdschrift Voor Geneeskunde|June 16, 1999
[Risk factors for dying among ibopamine users]P A de Graeff, A J Elferink, J F Lekkerkerker
Diabetologia|December 15, 2010
Rosiglitazone: a European regulatory perspectiveE Blind, K Dunder, P A de Graeff, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 25, 1995
[Consensus heart failure. Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing]P A de Graeff, A H Balk, W J Remme
International Journal of Technology Assessment in Health Care|January 5, 2002
Assessment of new cardiovascular drugs. Relationships between considerations, professional characteristics, and prescribingN F Wieringa, P Denig, P A de Graeff, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 8, 1997
[Digoxin in chronic heart failure and sinus rhythm: is the end of the controversy in sight?]D J van Veldhuisen, P A de Graeff, H J Crijns
Nederlands Tijdschrift Voor Geneeskunde|April 13, 1996
[Treatment of Angina pectoris using nitrates]J van Wijngaarden, D J van Veldhuisen, P A de Graeff
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Nederlands Tijdschrift Voor Geneeskunde|June 1, 1985
[The dangers of the sudden discontinuation of drugs]P A de Graeff
Agents and Actions. Supplements|January 1, 1992
The effect of bradykinin on coronary flow and its potentiation by SH-containing ACE-inhibitorsP A de Graeff, W H van Gilst
Agents and Actions. Supplements|January 1, 1992
Early ACE-inhibition in myocardial infarction. Possible role of bradykininW H van Gilst, P A de Graeff
Pharmacy World & Science : PWS|May 10, 2001
Comparative trials in registration files of cardiovascular drugs: comparator drugs and dosing schemesN F Wieringa, R Vos, P A de Graeff
Nederlands Tijdschrift Voor Geneeskunde|June 16, 1999
[Risk factors for dying among ibopamine users]P A de Graeff, A J Elferink, J F Lekkerkerker
Diabetologia|December 15, 2010
Rosiglitazone: a European regulatory perspectiveE Blind, K Dunder, P A de Graeff, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 25, 1995
[Consensus heart failure. Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing]P A de Graeff, A H Balk, W J Remme
International Journal of Technology Assessment in Health Care|January 5, 2002
Assessment of new cardiovascular drugs. Relationships between considerations, professional characteristics, and prescribingN F Wieringa, P Denig, P A de Graeff, et al.
Nederlands Tijdschrift Voor Geneeskunde|March 8, 1997
[Digoxin in chronic heart failure and sinus rhythm: is the end of the controversy in sight?]D J van Veldhuisen, P A de Graeff, H J Crijns
Nederlands Tijdschrift Voor Geneeskunde|April 13, 1996
[Treatment of Angina pectoris using nitrates]J van Wijngaarden, D J van Veldhuisen, P A de Graeff
Pageof 9